EA201491752A1 - Вакцина против rsv - Google Patents

Вакцина против rsv

Info

Publication number
EA201491752A1
EA201491752A1 EA201491752A EA201491752A EA201491752A1 EA 201491752 A1 EA201491752 A1 EA 201491752A1 EA 201491752 A EA201491752 A EA 201491752A EA 201491752 A EA201491752 A EA 201491752A EA 201491752 A1 EA201491752 A1 EA 201491752A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine against
against rsv
rsv
vaccine
nucleic acid
Prior art date
Application number
EA201491752A
Other languages
English (en)
Other versions
EA026620B1 (ru
Inventor
Катарина Радошевич
Жером Х.Х.В. Кустерс
Йорт Веллинга
Мира Н. Виджожоатмоджо
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA201491752A1 publication Critical patent/EA201491752A1/ru
Publication of EA026620B1 publication Critical patent/EA026620B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение предлагает вакцину против респираторно-синцитиального вируса (RSV), содержащую рекомбинантный аденовирус человека серотипа, который содержит нуклеиновую кислоту, кодирующую белок F RSV или его иммунологически активную часть.
EA201491752A 2012-03-22 2013-03-21 Вакцина против rsv EA026620B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614429P 2012-03-22 2012-03-22
EP12160682 2012-03-22
PCT/EP2013/055943 WO2013139916A1 (en) 2012-03-22 2013-03-21 Vaccine against rsv

Publications (2)

Publication Number Publication Date
EA201491752A1 true EA201491752A1 (ru) 2015-02-27
EA026620B1 EA026620B1 (ru) 2017-04-28

Family

ID=49221877

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201491752A EA026620B1 (ru) 2012-03-22 2013-03-21 Вакцина против rsv
EA201491754A EA026504B1 (ru) 2012-03-22 2013-03-21 Вакцина против rsv

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201491754A EA026504B1 (ru) 2012-03-22 2013-03-21 Вакцина против rsv

Country Status (15)

Country Link
EP (2) EP2827894B1 (ru)
JP (2) JP5845376B2 (ru)
KR (2) KR102023791B1 (ru)
CN (2) CN105431169B (ru)
AP (2) AP2014007993A0 (ru)
AR (2) AR090470A1 (ru)
AU (2) AU2013237424B2 (ru)
BR (1) BR112014023196B1 (ru)
CA (2) CA2867950C (ru)
EA (2) EA026620B1 (ru)
MY (2) MY169352A (ru)
NZ (2) NZ630753A (ru)
SG (2) SG11201405803PA (ru)
TW (2) TWI640534B (ru)
WO (2) WO2013139916A1 (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211756T1 (hr) 2012-07-05 2022-02-18 Glaxosmithkline Biologicals Sa Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi
US20160144021A1 (en) * 2013-04-08 2016-05-26 Medimmune, Llc Vaccine Composition And Method Of Use
EA035522B1 (ru) 2013-04-25 2020-06-29 Янссен Вэксинс Энд Превеншн Б.В. Стабильные растворимые f-полипептиды rsv в конформации "до слияния"
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3154576A1 (en) * 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
EP3283634B1 (en) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2988654A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
AU2016379097C1 (en) 2015-12-23 2021-04-08 Pfizer Inc. RSV F protein mutants
PE20190420A1 (es) 2016-04-05 2019-03-19 Janssen Vaccines And Prevention B V Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
IL262109B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
EP3455358B1 (en) 2016-05-12 2020-08-26 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
MY194419A (en) 2016-05-30 2022-11-30 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
EP3624844A1 (en) * 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
MX2020002876A (es) * 2017-09-15 2020-07-22 Janssen Vaccines & Prevention Bv Metodo para la induccion segura de inmunidad contra el vsr.
WO2020229579A1 (en) * 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
CN113924113A (zh) * 2019-05-15 2022-01-11 扬森疫苗与预防公司 季节性流感疫苗与基于腺病毒的呼吸道合胞病毒疫苗的共同施用
CA3182703A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
EP4003414A4 (en) * 2020-08-22 2023-05-10 Fed. State Budgetary Institution "Nat. Res. Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya" of the .... MEDICATIONS TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-COV-2
RU2731342C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
EP4010018A4 (en) * 2020-08-22 2022-11-09 Fed. State Budgetary Institution "Nat. Res. Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya" of the .... EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 VIRUS
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
WO2022215436A1 (ja) * 2021-04-05 2022-10-13 株式会社クボタ 管理機制御システム
WO2023217189A2 (zh) * 2022-05-10 2023-11-16 康希诺生物股份公司 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
CN117986382A (zh) * 2022-11-04 2024-05-07 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1760151B1 (en) 1996-11-20 2012-03-21 Crucell Holland B.V. Adenovirus compositions obtainable by an improved production and purification method
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
WO1999041416A2 (en) 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
PT1816204E (pt) 1999-05-17 2011-01-24 Crucell Holland Bv Adenovírus recombinante do serótipo ad26
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
AR038153A1 (es) 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
DE60313451T2 (de) 2002-05-14 2008-01-03 Merck & Co., Inc. Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1670925B1 (en) * 2003-10-02 2013-05-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
BR122013008865B8 (pt) * 2004-05-26 2021-05-25 Psioxus Therapeutics Ltd adenovírus oncolítico de replicação competente
ATE492643T1 (de) * 2004-10-13 2011-01-15 Crucell Holland Bv Verbesserte adenovirusvektoren und deren verwendung
JP2008538894A (ja) * 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
ES2317517T5 (es) 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101012463A (zh) * 2007-01-19 2007-08-08 安徽医科大学 HDAd/F载体及制备方法和用途
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
PL2488636T3 (pl) 2009-10-15 2014-07-31 Crucell Holland Bv Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym
JP5465331B2 (ja) 2009-10-15 2014-04-09 クルセル ホランド ベー ヴェー 高細胞密度の培養物からのアデノウイルスの精製方法
JP5917402B2 (ja) * 2009-11-03 2016-05-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine

Also Published As

Publication number Publication date
TW201343669A (zh) 2013-11-01
AU2013237424A1 (en) 2014-10-16
EA201491754A1 (ru) 2014-12-30
KR20140138765A (ko) 2014-12-04
AP2014007993A0 (en) 2014-10-31
WO2013139916A1 (en) 2013-09-26
KR102023791B1 (ko) 2019-09-23
TWI640534B (zh) 2018-11-11
AP2014007994A0 (en) 2014-10-31
KR20140138769A (ko) 2014-12-04
CN104334188A (zh) 2015-02-04
EP2827894A1 (en) 2015-01-28
TWI624545B (zh) 2018-05-21
JP2015519295A (ja) 2015-07-09
NZ630649A (en) 2016-12-23
EP2827895A1 (en) 2015-01-28
BR112014023196A2 (ru) 2017-06-20
KR102050616B1 (ko) 2019-12-03
MY169331A (en) 2019-03-21
MY169352A (en) 2019-03-25
EA026504B1 (ru) 2017-04-28
BR112014023196B1 (pt) 2021-09-08
AU2013237429A1 (en) 2014-10-09
CN105431169A (zh) 2016-03-23
CA2867955C (en) 2023-02-07
SG11201405803PA (en) 2014-11-27
CN104334188B (zh) 2016-08-24
CA2867950A1 (en) 2013-09-26
CA2867955A1 (en) 2013-09-26
NZ630753A (en) 2016-12-23
EP2827894B1 (en) 2017-05-17
AU2013237429B2 (en) 2015-07-23
JP5805908B2 (ja) 2015-11-10
SG11201405804YA (en) 2014-10-30
JP2015512380A (ja) 2015-04-27
EP2827895B1 (en) 2017-08-09
WO2013139911A1 (en) 2013-09-26
AR090469A1 (es) 2014-11-12
CA2867950C (en) 2023-02-21
TW201341531A (zh) 2013-10-16
AU2013237424B2 (en) 2017-07-06
JP5845376B2 (ja) 2016-01-20
CN105431169B (zh) 2019-04-02
EA026620B1 (ru) 2017-04-28
AR090470A1 (es) 2014-11-12

Similar Documents

Publication Publication Date Title
EA201491752A1 (ru) Вакцина против rsv
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
EA201890527A1 (ru) Терапевтические вакцины против hpv18
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
MA43108A (fr) Anticorps neutralisant le virus syncytial respiratoire humain
WO2012024621A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
HK1205459A1 (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine (mva)(rsv)
EA201390866A1 (ru) Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35
ATE461710T1 (de) Nipah-virus-impfstoffe
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112018012642A2 (pt) vacina de calicivírus felino
EP2970942A4 (en) Polysialic acid, blood group antigens and glycoprotein expression
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
WO2015041924A8 (en) Recombinant respiratory syncytial virus (rsv) and vaccines
PH12014502086A1 (en) Vaccine against rsv
ITUA20161610A1 (it) Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
ZA201500606B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
Druzhinina Theatre and Cultural Center" Olkhon" at Baikal
TH1101001042B (th) รีคอมบิเเนนท์เวคเตอร์ซึ่งประกอบด้วยยีนที่เข้ารหัสฮิวเเมน กลูโคไคเนส
TH66676B (th) อุปกรณ์การบำบัดด้วยความร้อนแบบสุญญากาศ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM